{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01725165\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"OLIGOMEZ","nct_id":"NCT01725165","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=oligomez-nct01725165. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo ablation of all residual local and metastatic sites of disease by surgery and/or EBRT. After completion of LCT, patients undergo either surveillance or maintenance treatment at the discretion of the treating physician.","label":"Arm I (immediate LCT)","type":"EXPERIMENTAL"},{"description":"Patients undergo standard maintenance therapy or clinical observation, based on physician choice. Patients may cross-over to Arm I due to RECIST progression or toxicity at the treating physician's discretion.","label":"Arm II (delayed/no LCT)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2024-05-08","type":"ACTUAL"},"conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Non-Small Cell Lung Cancer AJCC v7"],"enrollment":{"count":85,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Clinical Observation","otherNames":["observation"],"type":"OTHER"},{"name":"External Beam Radiation Therapy","otherNames":["Definitive Radiation Therapy","EBRT","External Beam Radiotherapy","External Beam RT","external radiation","External Radiation Therapy","external-beam radiation"],"type":"RADIATION"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Standard Follow-Up Care","otherNames":[],"type":"PROCEDURE"},{"name":"Therapeutic Conventional Surgery","otherNames":[],"type":"PROCEDURE"}],"last_update":"2024-10-24","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-05-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"16.6 months to 41.2 months for all patients in both LCT and MT/O group"}],"references":[{"citation":"Tang C, Lee WC, Reuben A, Chang L, Tran H, Little L, Gumbs C, Wargo J, Futreal A, Liao Z, Xia X, Yi X, Swisher SG, Heymach JV, Gomez D, Zhang J. Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):349-357. doi: 10.1016/j.ijrobp.2019.10.038. Epub 2019 Oct 31.","pmid":"31678224","type":"DERIVED"},{"citation":"Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.","pmid":"27789196","type":"DERIVED"}],"start_date":{"date":"2012-11-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT01725165"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/oligomez-nct01725165"}